A Study of PRO95780 in Patients With Previously Untreated, Advanced-Stage Non-Small Cell Lung Cancer (APM4074g)

NCT00480831 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

128

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: bevacizumab
DRUG: carboplatin
DRUG: paclitaxel
DRUG: placebo
DRUG: PRO95780

Sponsor

Genentech, Inc.